| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.417 | 0 | 0 | 1.123 | 1.201 | 835 | 1.152 | 1.156 | 1.152 | 1.146 |
| Total Income - EUR | 1.424 | 2 | 0 | 1.123 | 1.201 | 835 | 1.152 | 1.156 | 1.152 | 1.146 |
| Total Expenses - EUR | 1.893 | 107 | 41 | 279 | 0 | 124 | 1.751 | 345 | 1.895 | 838 |
| Gross Profit/Loss - EUR | -470 | -105 | -41 | 844 | 1.201 | 711 | -599 | 811 | -743 | 308 |
| Net Profit/Loss - EUR | -512 | -105 | -41 | 810 | 1.165 | 687 | -634 | 777 | -750 | 230 |
| Employees | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Labmedlex S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 94 | 66 | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 5.425 | 96 | 78 | 935 | 2.082 | 2.729 | 2.035 | 2.817 | 1.903 | 2.298 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 0 |
| Cash | 5.408 | 96 | 78 | 935 | 2.082 | 2.729 | 2.035 | 2.817 | 1.881 | 2.298 |
| Shareholders Funds | 4.094 | 162 | 118 | 926 | 2.073 | 2.720 | 2.026 | 2.809 | 2.051 | 2.269 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 1.425 | 0 | 0 | 9 | 9 | 9 | 9 | 8 | 0 | 29 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Labmedlex S.r.l.